TRACE AMINE-ASSOCIATED RECEPTOR 1 IS A MODULATOR OF BRAIN MONOAMINERGIC SYSTEMS

微量胺相关受体 1 是大脑单胺能系统的调节剂

• 批准号: 8357909
• 负责人: GREGORY MICHAEL MILLER
• 金额: $ 1.64万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357909
• 关键词: Amines; Behavioral; Brain; Disease; Funding; Genetic; Grant; Human; Modeling; National Center for Research Resources; Neurobiology; New England; Physiological; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Rodent; Role; Source; Structure; System; Therapeutic Agents; Transgenic Organisms; United States National Institutes of Health; addiction; base; cost; neuropsychiatry; nonhuman primate; novel; receptor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. As human and rodent trace amine receptors diverge in structure, subtype number and brain distribution, we postulate that non-human primates will provide a more suitable model for uncovering the physiological and pharmacological relevance of trace amine subtypes. In this regard, there is a 96 percent sequence identity for Trace Amine Associated Receptor 1 (TAAR1) in non-human primate and human. We are investigating the fundamental neurobiological roles of TAAR1 in mammalian brain and behavioral effects resulting from its activation or deletion using pharmacological, cellular, genetic, anatomical, transgenic and behavioral approaches. Our studies form the basis for investigating the physiological and pharmacological relevance of trace amine receptors in the primate model, and provide novel leads for developing therapeutic agents to treat addiction and neuropsychiatric disorders.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 由于人类和啮齿动物的微量胺受体在结构、亚型数量和大脑分布方面存在差异，我们假设非人类灵长类动物将为揭示微量胺亚型的生理和药理学相关性提供更合适的模型。在这方面，非人类灵长类动物和人类的痕量胺相关受体 1 (TAAR1) 具有 96% 的序列同一性。我们正在利用药理学、细胞、遗传、解剖学、转基因和行为方法研究 TAAR1 在哺乳动物大脑中的基本神经生物学作用以及由于其激活或缺失而产生的行为效应。我们的研究奠定了研究灵长类动物模型中痕量胺受体的生理和药理学相关性的基础，并为开发治疗成瘾和神经精神疾病的治疗药物提供了新的线索。